Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.66 |
| ▸ | DHFR | P00374 | 8/20 | 0.63 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6115548 | 0.99 | TP53 (0.97) | TP53CYP2D6SMN1; SMN2HIF1APPP3CB | |
| SCHEMBL1936223 | 0.96 | TP53 (0.92) | TP53CYP2D6SMN1; SMN2HIF1APPP3CB | |
| Hydrochloric Acid SCHEMBL8986139 | 0.94 | TP53 (0.90) | TP53CYP2D6SMN1; SMN2HIF1APPP3CB | |
| SCHEMBL672319 | 0.81 | DHFR (0.73) | TP53CYP2D6SMN1; SMN2HIF1APPP3CB | |
| SCHEMBL16102719 | 0.80 | PPP3CB (1.00) | TP53CYP2D6SMN1; SMN2HIF1APPP3CB | |
| SCHEMBL28754650 | 0.70 | DHFR (0.54) | TP53CYP2D6SMN1; SMN2HIF1APPP3CB | |
| SCHEMBL28637690 | 0.69 | TP53 (0.53) | TP53CYP2D6SMN1; SMN2HIF1APPP3CB | |
| SCHEMBL672667 | 0.68 | DHFR (0.52) | TP53CYP2D6SMN1; SMN2HIF1ADHFR | |
| Hydrochloric Acid SCHEMBL8934038 | 0.68 | DHFR (1.00) | DHFR | |
| SCHEMBL14577782 | 0.67 | DHFR (1.00) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| WO-2011014825-A2 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | TP53 356/4885CYP2D6 4837/4885SMN1; SMN2 2548/4885 |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | TP53 356/4885CYP2D6 4837/4885SMN1; SMN2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.